Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
J. M. Flynn, S. N. Zvornicanin, A. M. Shaqra…·D. Bolon
This study identifies hyperactive mutations in SARS-CoV-2 Mpro that increase enzyme activity and contribute to drug resistance, finding them more prevalent than binding-reducing mutations.
S. N. Zvornicanin, A. M. Shaqra, Q. Y. Huang…·N. Kurt Yilmaz
The paper determines inhibitor-bound crystal structures of main proteases from delta and gamma coronaviruses to inform structure-based inhibitor design.
A. M. Shaqra, S. Zvornicanin, Q. Y. Huang…·C. A. Schiffer
This study defines the substrate envelope of SARS-CoV-2 main protease using cocrystal structures to identify vulnerable sites that may lead to drug resistance.
M. Ejemel, Q. Li, S. Hou…·Y. Wang
This study identifies an IgA monoclonal antibody that blocks SARS-CoV-2 Spike-ACE2 interaction and provides mucosal immunity.
S. Hou, T. V. Silvas, F. Leidner…·C. A. Schiffer
This study identifies the structural basis for APOBEC3B's lower catalytic activity and DNA binding through molecular modeling and mutational analysis.
T. V. Silvas, S. Hou, W. Myint…·C. A. Schiffer
This study identifies the APOBEC3A ssDNA binding motif and shows that substrate affinity is influenced by DNA structure, not just sequence, leading to a new model for its sequence preference.